Literature DB >> 16210846

IGF-1 and retinopathy of prematurity in the preterm infant.

Lois E H Smith1.   

Abstract

BACKGROUND: Retinopathy of prematurity (ROP) continues to be a major cause of blindness in children. Although ablation of the retina reduces the incidence of blindness by suppressing the neovascular phase of ROP, the visual outcomes after treatment are often poor. Preventive therapy is required and will likely come from a better understanding of the pathophysiology of the disease.
OBJECTIVES: To study the role of insulin-like growth factor 1 (IGF-1) and vascular endothelial growth factor (VEGF) in both the proliferative phase of ROP (phase II) and in the early phase when blood vessels are lost.
METHODS: Using both a mouse model of ROP and clinical studies the relationship between IGF-1, VEGF and both vessel loss and vessels proliferation in the retina was studied.
RESULTS: IGF-1 is required for maximum VEGF activation of vascular endothelial cell proliferation and survival pathways. IGF-1 levels are deficient after premature birth, setting the stage for retinal vascular loss and ROP.
CONCLUSIONS: Restoration of IGF-1 to levels found in utero may help prevent ROP. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210846     DOI: 10.1159/000087587

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  28 in total

1.  Vitamin D deficiency exacerbates experimental stroke injury and dysregulates ischemia-induced inflammation in adult rats.

Authors:  Robyn Balden; Amutha Selvamani; Farida Sohrabji
Journal:  Endocrinology       Date:  2012-03-09       Impact factor: 4.736

Review 2.  Revisiting the timing hypothesis: biomarkers that define the therapeutic window of estrogen for stroke.

Authors:  Farida Sohrabji; Amutha Selvamani; Robyn Balden
Journal:  Horm Behav       Date:  2012-06-19       Impact factor: 3.587

Review 3.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

Review 4.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

5.  The role of hemoglobin variant replacement in retinopathy of prematurity.

Authors:  Wojciech Podraza; Hanna Podraza; Karolina Jezierska; Joanna Szwed; Monika Modrzejewska; Jacek Rudnicki; Agnieszka Kordek; Hanna Domek
Journal:  Indian J Pediatr       Date:  2011-06-01       Impact factor: 1.967

Review 6.  The putative role of lutein and zeaxanthin as protective agents against age-related macular degeneration: promise of molecular genetics for guiding mechanistic and translational research in the field.

Authors:  John Paul SanGiovanni; Martha Neuringer
Journal:  Am J Clin Nutr       Date:  2012-10-10       Impact factor: 7.045

7.  The neurotoxic effects of estrogen on ischemic stroke in older female rats is associated with age-dependent loss of insulin-like growth factor-1.

Authors:  Amutha Selvamani; Farida Sohrabji
Journal:  J Neurosci       Date:  2010-05-19       Impact factor: 6.167

8.  Posterior to the ridge laser treatment for severe stage 3 retinopathy of prematurity.

Authors:  A L Ells; G A Gole; P Lloyd Hildebrand; A Ingram; C M Wilson; R Geoff Williams
Journal:  Eye (Lond)       Date:  2013-01-18       Impact factor: 3.775

9.  The role of serial measurements of serum insulin-like growth factor 1 levels in the development of retinopathy of prematurity.

Authors:  Bayram Ali Dorum; Cansu Canbolat Yılmaz; Nilgün Köksal; Hilal Özkan; Meral Yıldız; Ahmet Tuncer Özmen
Journal:  Turk Pediatri Ars       Date:  2017-03-01

10.  Age-associated increase in cleaved caspase 3 despite phosphorylation of IGF-1 receptor in the rat retina.

Authors:  Youde Jiang; Robert J Walker; Jena J Steinle
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-08-20       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.